Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2047-783X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review ; volume:27 ; number:1 ; day:4 ; month:6 ; year:2022 ; pages:1-16 ; date:12.2022
European journal of medical research ; 27, Heft 1 (4.6.2022), 1-16, 12.2022
- Urheber
-
Sevivas, Hugo
Fresco, Paula
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40001-022-00716-w
- URN
-
urn:nbn:de:101:1-2022080320383057372286
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sevivas, Hugo
- Fresco, Paula
- SpringerLink (Online service)
Ähnliche Objekte (12)
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Monoclonal antibodies for migraine: an update
Inflammatory complications of CGRP monoclonal antibodies: a case series
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Monoclonal antibodies for migraine: an update
Inflammatory complications of CGRP monoclonal antibodies: a case series
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Monoclonal antibodies for migraine: an update
Inflammatory complications of CGRP monoclonal antibodies: a case series
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study